MedTrace Logo

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

NCT01500018 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-03-22

No results posted yet for this study

Summary

This is a single dose, crossover study to assess the abuse potential of TC-5214 compared to placebo, ketamine, and phentermine in healthy recreational polydrug users.

Conditions

  • Drug Abuse
  • Healthy

Interventions

DRUG

TC-5214

Single oral dose of 2 mg

DRUG

TC-5214 Placebo

Single oral dose

DRUG

Ketamine

Single oral dose of 100 mg

DRUG

Phentermine

Single oral dose of 45 mg

DRUG

TC-5214

Single oral dose of 8 mg

DRUG

TC-5214

Single oral dose of 16 mg

DRUG

Phentermine

Single oral dose of 90 mg

Sponsors & Collaborators

Principal Investigators

  • Hans A Eriksson, MD · AstraZeneca Kvzmbergagatan 12, 15185,Sodertalje, Sweden

  • Pierre Geoffroy, MDCM, MSC, FCFP · Syneos Health

  • Brendan Smyth, MD · AstraZeneca 180 Concord Pike, Wilmington,DE 19850-5437

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-04-30
Completion
2012-04-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01500018 on ClinicalTrials.gov